Skip to main content

argenx SE

corporate_fare Company Profile

argenx SE

ARGX·NASDAQ·Life Sciences·CIK 0001697862

argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx SE is also developing efgartigimod for seronegative gMG, ocular myasthenia gravis (MG), primary ITP, Grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR. Other pipeline candidates include empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. The company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody; ARGX-124, another FcRn pipeline candidate; ARGX-109, which targets IL-6 for inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10. Additional developments include cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. argenx SE has strategic partnerships and license agreements with Zai Lab for efgartigimod; Halozyme Therapeutics for its ENHANZE technology; OncoVerity, Inc. for cusatuzumab; and AbbVie, Inc. for ARGX-115. The company was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE (NASDAQ:ARGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ARGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for ARGX spans 6-K, SC TO-T/A, SC TO-T, 20-F.

Recent high-impact activity:

  • argenx Details ALKIVIA Phase 3 Data at ACR; IMNM sBLA Planned by End-2026
  • argenx to Buy Unnatural Products for $550M Upfront, Up to $1.15B Total
  • argenx Q3: VYVGART Sales Up 54% to $1.7B, FY26 Spend Guidance ~$4B
  • Argenx Halts Phase 3 Sjögren's Trial, Shares Plunge 14%
  • argenx: FB102 Phase 2 Win in Celiac, But UNITY Sjögren's Study Fails

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
$1.29B
Diluted EPS
$19.57
Op. Cash Flow
$685.19M
Free Cash Flow
$679.03M
Operating Income
$1.05B
Cash & Equivalents
$3.49B
Debt / Equity
0.00×
Shares Outstanding
61.88M sh
Source: 20-F · filed 2026-03-19 · accession 0001697862-26-000032

Short Interest & Short Volume

3.42 days to cover

FINRA reported short interest of 1,412,594 shares in ARGX as of the October 30, 2026 settlement, a 4.3% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 48.1% of ARGX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,412,594 shares as of October 30, 2026
Change vs prior period▲ 4.3%
Days to cover3.42 at avg daily volume of 413,048
Daily short volume (FINRA facilities)48.1% of 86,022 shares on November 20, 2026
5-day average short volume61.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

ARGX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$925.7
52-week range · as of 2026-11-09 $661.85 – $1072.75
Market cap
$58.8B
Volume
249.7K (0.6× avg)
3-mo avg 389.8K
Live data · 2026-11-22 07:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARGX - Latest Insights

ARGX
Nov 09, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $945.64
Real-time Price: $925.70 info
Change: -$19.94 (-2%) info
Market Cap: $58.801B info
ARGX
Nov 09, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $894.64
Real-time Price: $925.70 info
Change: +$31.06 (+3%) info
Market Cap: $58.801B info
ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $925.70 info
Change: +$71.70 (+8%) info
Market Cap: $58.801B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $925.70 info
Change: +$130.50 (+16%) info
Market Cap: $58.801B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $925.70 info
Change: +$134.70 (+17%) info
Market Cap: $58.801B info
ARGX
Sep 29, 2026, 8:38 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $970.55
Real-time Price: $925.70 info
Change: -$44.85 (-5%) info
Market Cap: $58.801B info
ARGX
Aug 27, 2026, 9:27 AM EDT
Filing Type: SC TO-T/A
Importance Score:
8
Price at Filing: $1,018.58
Real-time Price: $925.70 info
Change: -$92.88 (-9%) info
Market Cap: $58.801B info
ARGX
Aug 19, 2026, 7:48 AM EDT
Filing Type: SC TO-T/A
Importance Score:
7
Price at Filing: $1,015.76
Real-time Price: $925.70 info
Change: -$90.06 (-9%) info
Market Cap: $58.801B info
ARGX
Aug 17, 2026, 8:54 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $955.02
Real-time Price: $925.70 info
Change: -$29.32 (-3%) info
Market Cap: $58.801B info
ARGX
Aug 06, 2026, 7:06 AM EDT
Filing Type: SC TO-T
Importance Score:
9
Price at Filing: $868.54
Real-time Price: $925.70 info
Change: +$57.16 (+7%) info
Market Cap: $58.801B info
ARGX
Jul 27, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $939.84
Real-time Price: $925.70 info
Change: -$14.14 (-2%) info
Market Cap: $58.801B info
ARGX
Jul 23, 2026, 8:21 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $876.27
Real-time Price: $925.70 info
Change: +$49.43 (+6%) info
Market Cap: $58.801B info
ARGX
Jun 03, 2026, 7:16 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $790.71
Real-time Price: $925.70 info
Change: +$134.99 (+17%) info
Market Cap: $58.801B info
ARGX
Jun 03, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $802.17
Real-time Price: $925.70 info
Change: +$123.53 (+15%) info
Market Cap: $58.801B info
ARGX
May 08, 2026, 5:20 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $790.00
Real-time Price: $925.70 info
Change: +$135.70 (+17%) info
Market Cap: $58.801B info
ARGX
May 07, 2026, 8:46 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $822.71
Real-time Price: $925.70 info
Change: +$102.99 (+13%) info
Market Cap: $58.801B info
ARGX
May 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $807.55
Real-time Price: $925.70 info
Change: +$118.15 (+15%) info
Market Cap: $58.801B info
ARGX
May 06, 2026, 4:28 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $807.55
Real-time Price: $925.70 info
Change: +$118.15 (+15%) info
Market Cap: $58.801B info
ARGX
Apr 18, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $849.04
Real-time Price: $925.70 info
Change: +$76.66 (+9%) info
Market Cap: $58.801B info
ARGX
Mar 19, 2026, 6:13 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $679.85
Real-time Price: $925.70 info
Change: +$245.85 (+36%) info
Market Cap: $58.801B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets